The aim of this study was to investigate whether impaired flow mediated vasodilation precedes the clinical manifestations of preeclampsia and whether is associated with inflammation.
P
regnancy-induced hypertension (PIH) is the most frequent complication in pregnancy after the 20 th week of gestation. This form of hypertension is classified as preeclampsia (PE) and gestational hypertension (GH). The latter is defined as the acute development of hypertension in a woman whose blood pressure (BP) was normal in the early stages of pregnancy and who subsequently developed persistent elevation of BP to at least 140/90 mm Hg. Both GH and concomitant 24-h proteinuria (0.3 g/L or more) in the absence of urinary tract infection is defined as PE. 1 The condition of PE is the main cause of maternal and perinatal mortality, low birth weight, and intrauterine growth restriction, whereas GH has been associated with increased rates of preterm delivery and small-forgestational-age infants. 2 Despite the importance of PIH for public health, the etiology of the disease remains unknown. 3 Normal pregnancy is associated with a decreased systemic vascular resistance and increased cardiac output, blood volume, renal flow, and glomerular filtration. 4 In PE there is an increased systemic vascular and uteroplacental circulation resistance probably related with alterations in the L-arginine-NO-cyclic GMP pathway. 5 Recently, there has been a growing interest in the role of inflammation as a key factor of endothelial dysfunction.
A generalized activation of circulating leukocytes, characteristic of inflammation, has been found during PE. 6 Moreover, increased concentrations of C-reactive protein (CRP) and inflammatory cytokines have been reported in preeclamptic women. 7 Flow-mediated dilation (FMD), a noninvasive method that uses high-resolution ultrasonography, is an established test to assess endothelial function. The FMD technique measures the changes in the brachial artery diameter as a response to shear stress, and is partially dependent on the capacity of endothelial cells to release nitric oxide (NO). 8 This method has been recently validated in Colombian population. 9, 10 Former reports have shown that FMD of the brachial artery is enhanced in normal pregnancy, whereas this response is impaired in women with PE. [11] [12] [13] [14] [15] [16] However, these studies have not established whether impaired FMD is a cause or a consequence of the disease. Moreover, the factors that produce endothelial damage have not yet been clearly identified. Thus, the purpose of this study was to investigate whether FMD impairment and inflammation precede the manifestations of PE.
Methods

Participants
We conducted a nested case-control study in a prospective cohort of 506 unrelated Hispanic pregnant women who were recruited from March 2001 to June 2005 at the Doppler Ultrasound Department of the Cardiovascular Foundation of Colombia, Bucaramanga, Colombia. The inclusion criteria for recruitment were gestational age Յ30 weeks and the presence of at least one of the following criteria of risk: age Յ25 or Ն35 years of age, primigravidae, past history of preeclampsia, and family antecedents of preeclampsia. None of the patients had multiple pregnancy, diastolic BP of Ն85 mm Hg at study entry, cardiovascular or renal disease, or hypertension, and none were taking any medication at the time that they were enrolled. The study was approved by the local institutional review board, and all subjects gave written informed consent before entering the study.
Flow-Mediated Dilation
Flow-mediated dilation assessment was performed at study entry according to the recommendations of the International Brachial Artery Reactivity Task Force. 17 All measures were performed in a temperature-controlled room (24°C), from 7 AM to 10 AM, with a fasting period of at least 10 h for all the subjects. The study was performed after 10 min of rest with the subject in a supine position. The left arm was comfortably immobilized in the extended position to allow consistent access to brachial artery for imaging. Brachial artery diameter and blood flow velocity were imaged using a 7.5-MHz linear-array transducer ultrasound system (Aloka, vario view SDD2200, Tokyo, Japan), located between four and ten cm above the antecubital fossa. A baseline measurement of brachial artery diameter was obtained, as well as a baseline measurement of the velocity of the arterial flow by means of a pulsed Doppler signal at a 70°angle to the vessel.
After baseline measurements, a small-width BP cuff was inflated on the most proximal portion of the forearm to occlusive pressure (300 mm Hg) for 5 min to induce hyperemia. Recently, we have demonstrated that the location of the occlusion device in FMD did not affect the diagnosis accuracy to differentiate subjects with and without cardiovascular risk factors. Moreover, a significant correlation between upper arm and upper forearm locations of the occlusive device was observed. 18 The cuff was then deflated and pulsed Doppler signals were recorded for 15 sec. Images of the brachial artery were obtained after 60 sec of cuff deflation. Vessel diameters were measured with ultrasonic calipers from the leading edge of the anterior wall to the leading edge of the posterior wall of the brachial artery at end diastole, incident with the R wave on the simultaneously recorded electrocardiogram. Changes in diameter were calculated as percentages of change relative to the baseline diameter using the following equation: [(vessel diameter after cuff deflation Ϫ resting vessel diameter)/resting vessel diameter] ϫ 100%. The flow velocity was taken from the center of the vessel. Reactive hyperemia was calculated as follows: [(blood flow at 15 sec after cuff deflation Ϫ resting blood flow)/ resting blood flow] ϫ 100%. In our laboratory, the FMD has shown to be a precise and reproducible technique. 9 All images were recorded on Super VHS tape for later analysis. The studies were subsequently analyzed by two blinded observers; the mean values obtained from the two observers were used for analysis.
Biochemical Determinations
At study entry, blood samples were withdrawn early in the morning from the antecubital vein after a fasting period of 10 h in 10-mL vacutainer tubes before the FMD study. Plasma was separated by centrifugation for 15 min and then was frozen at Ϫ70°C and stored until analysis. An aliquot of whole blood was taken to determine platelet and leukocyte counts in an automatic counter (Baker System 9120 AX, Biochem Immunosystem, Allentown, PA). Plasma CRP concentrations were measured by high sensitive chemiluminescent immunometric assay in the samples of participants selected for the nested case-control study (Immulite 1000, DPC, Los Angeles, CA). All assays were performed by personnel blinded to case-control status.
Follow-Up
Patients were followed by telephone during the development of their pregnancy. After delivery, each patient's medical record was reviewed to confirm the presence or absence of PIH. We obtained information about the course of pregnancy, mode of delivery, infant birth weight, and postpartum BP was obtained from all women. Pregnancyinduced hypertension was defined by the presence of GH or PE. Preeclampsia was defined as normotension before 20 weeks gestation with the subsequent development of hypertension (Ն140/90 mm Hg) and significant concomitant 24-h proteinuria (Ն0.3 g/L) in the absence of urinary tract infection. Gestational hypertension was defined as de novo hypertension arising after mid-pregnancy without proteinuria. 1 A total of 32 pregnant women developed PIH (14 PE, 18 GH). Members of the cohort who remained normotensive and delivered after 37 weeks of gestation were eligible as control subjects. Two control subjects for every case were randomly selected, and matched by gestational age, maternal age, and body mass index at study entry. This ratio case:control allowed us to reach enough power for statistical analysis and to optimize resources.
Statistical Analysis
The whole group of matched control subjects (68 women who remained normotensive) was compared to each group of cases. Descriptive data were expressed as mean Ϯ SD. We used the Shapiro-Wilk test to assess the normality of continuous data. Continuous variables were analyzed using two-sample t tests or Wilcoxon rank-sum test, and categorical variables were analyzed using the 2 test or Fisher's exact test. Statistical significance was defined as P Ͻ .05. When more than two groups were compared one-way analysis of variance was used. To evaluate the association of FMD impairment and PE, potential confounders and other co-variables were entered in a multivariate logistic regression model. All data were analyzed using Stata statistical software, release 8.0 (Stata Corporation, College Station, TX).
Results
The mean age of the cohort at enrollment was 21.8 Ϯ 5.6 years. A total of 440 (86.96%) were Յ25 years of age and 46 women (9.09%) were Ն35 years of age. In all, 370 women (73.72%) were primigravidae. All subjects had normal systolic and diastolic BP. The clinical and FMD characteristics of pregnant women at enrollment are shown in Table 1 . Until delivery 474 women remained normotensive and 32 (6.32%) developed PIH [14 PE (2.77%) and 18 GH (3.56%)]. The mean age at enrollment was comparable between women who subsequently developed PIH and the group of women who remained normotensive (Table 2) . Also, there were no significant differences in ethnicity and body mass index. No women were current smokers. There were no differences in passive exposure to tobacco smoke between the groups of women with PE, GH, and normotensive pregnant control subjects. Basal characteristics of women who subsequently developed GH or PE, and normal pregnant women are shown in Table 2 . No significant differences in FMD values, CRP concentrations or leukocyte count at study entry were found between women who subsequently developed GH and normotensive pregnant control subjects (Table 2) . Women with GH presented higher values of systolic BP and diastolic BP at delivery when compared to control group (P Յ .0001). There were no significant differences in gestational age at delivery or birth weight between women who developed GH and normotensive pregnant women (Table 3) .
At enrollment, women who later on developed PE presented significantly higher concentrations of CRP (8.7 Ϯ 5.5 mg/L v 5.3 Ϯ 4.3 mg/L, P ϭ .02) and leukocyte count (10.3 Ϯ 2.0 (ϫ10 9 /L) v 9.1 Ϯ 2.0 (ϫ10 9 /L), P ϭ .04) than those found in normotensive control subjects (Fig. 1) . Moreover, in these women there was a higher rate of past history of PE and family history of hypertension. FMD was significantly lower in women who subsequently developed preeclampsia (13.4% Ϯ 4.3% v 18.2% Ϯ 7.2%, P ϭ .03) than in those from the control group (Table 2 ). In addition, we observed that the relation between FMD and PE was not influenced by potential confounders such as BP values at enrollment (SBP: P ϭ .19; DBP: P ϭ .54), CRP levels (P ϭ .78) and leukocyte count (P ϭ .75) in a multivariate logistic regression model. No significant differences were found in basal blood flow and reactive hyperemia values. The patients who subsequently developed PE had a significantly higher BP at delivery when compared with normotensive control group (P Յ .0001), and presented proteinuria Ͼ300 mg/24 h. The interval between enrollment and development of preeclampsia had a mean of 15 ϩ 4.3 weeks. Women in the PE group had a shorter gestational period and a higher rate of cesarean delivery (Table 3 ). In women with GH as well as in those who developed PE, FMD showed no significant correlation either with CRP or with white blood cell count. 
Discussion
Endothelial dysfunction is considered to underlie many of the pathologic mechanisms of PE. 19 Moreover, an impaired FMD has been showed in PE. [13] [14] [15] [16] However, most of these studies have been done in the clinical phase of the disease. Therefore they have failed in establishing a causal relationship between endothelial dysfunction and PE. Recently, two studies showed that FMD in the brachial artery measured during the second half of pregnancy predicts the subsequent development of PE in high-risk patients. 15, 16 However, these studies included pregnant women who presented other factors that could alter the FMD as old age, obesity, dyslipidemia, and smoking. Most of the women included in the present study, who subsequently developed PE were young, primigravidae, and had normal values of cholesterol, triglycerides, LDL and HDL cholesterol, glycemia and BP. Hence, we can confirm that the early impairment of FMD in pregnancy precedes the onset of clinical manifestations of PE. There were no significant differences in clinical or demographic characteristics of groups at baseline; hence it is unlikely that the impairment in FMD in women who subsequently developed PE could be explained by the influence of these factors.
Savvidou et al 15 reported elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in women with PE and suggested that high levels of ADMA are responsible for the impaired FMD in this disease. However, in our population we found no differences in plasma ADMA concentrations among women with PE and women with normal pregnancy. 5, 20 Thus, at least in our population, it is unlikely that ADMA has any etiologic role in the development of endothelial dysfunction and PE. It has been hypothesized that endothelial dysfunction in PE is part of a generalized intravascular inflammatory reaction involving intravascular leukocytes as well as the clotting and complement system, which can be considered as the extreme end of the range of maternal adaptation to pregnancy. 6 Gestational hypertension and PE are believed to have different pathophysiology, however, 15-46% of pregnant women initially diagnosed as having GH developed PE, suggesting that GH can represent an initial stage of a disease that can evolve into a major systemic dysfunction. 21 Wilczynski et al 22 found an increased decidual cytokine secretion in both PE and GH patients in comparison with normal pregnant women, suggesting that GH is an intermediate step to PE. In the present study we observed a progressive increase in CRP concentrations in GH and PE patients, but we failed to find a significant difference between GH patients and normal pregnant control subjects. However, our results demonstrated that CRP is more pronounced in the PE group. These results suggest that the extent of the inflammatory response is correlated with the severity of the disease.
We have proposed that endothelial dysfunction in PE could be related with the presence of raised concentrations of CRP and an abnormal cytokine response that alter the production and degradation of NO. 23 This proposal was based on studies performed in pregnant Andean women who were at high risk of developing PE and had increased levels of CRP, IL-6, TNF-␣, and higher leukocyte count and increased total number of neutrophils. 7 Our results showing that CRP and white blood cell count are increased early in pregnancy in women who subsequently developed PE support the proposal that PE is related with an inflammatory state. Moreover, recently Qiu et al 24 in a prospective nested case-control study, reported that women with CRP concentrations Ͼ4.9 mg/L had a 2.5-fold increased risk of presenting PE. In addition, Tjoa et al 25 demonstrated that elevated CRP levels during the first trimester of pregnancy are indicative of PE and intrauterine growth restriction.
C-reactive protein is a sensitive marker of overall inflammation in the body and is also associated with adiposity and body mass index. Wolf et al 26 reported that pregnant women with higher CRP concentrations presented an increased risk of PE, although after adjusting for pre-pregnancy body mass index, this association was attenuated. In the present study, the groups were matched by body mass index, thus the increased levels of CRP were caused by body weight. Although the endothelial dysfunction of PE has been associated to an exaggerated maternal inflammatory response to pregnancy, the underlying mechanism of this alteration has not been established. 5 It has been hypothesized that placental hypoxia, resulting from uteroplacental arterial insufficiency, amplifies release of inflammatory stimuli into the maternal circulation, involving lipid peroxidation, leukocyte activation, and stimulation of proinflammmatory cytokine production by the placenta. 27 Another proposed stimulus associated to inflammation in PE has been the presence of vaginal and/or urinary tract infections in pregnancy, including asymptomatic bacteriuria. 3, 23 Recently, we demonstrated that the antibiotic therapy to women with vaginal or urinary tract infection improved FMD and decreased the incidence of PE in women with subclinical infections. 28 In women of the present study, without infection, FMD showed no significant correlation either with CRP levels or with white blood cell count.
In conclusion, we have shown that raised CRP concentrations and decreased FMD in early pregnancy are associated with an increased risk of PE. Our results are consistent with the hypothesis that PE is caused by endothelial dysfunction and systemic inflammation during early pregnancy preceding the clinical manifestations of the disease. Further studies are needed to elucidate whether the determination of FMD and CRP in pregnancy could be useful methods to screen women at risk of developing PE.
